查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2017173

尿激酶市場：全球市場按產品類型、劑型、應用、最終用戶和分銷管道分類的預測 - 2026-2032 年

Urokinase Market by Product Type, Form, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，尿激酶市值將達到 19.5 億美元，到 2026 年將成長到 20.7 億美元，到 2032 年將達到 31.2 億美元，複合年成長率為 6.92%。

主要市場統計數據
基準年 2025 19.5億美元
預計年份：2026年 20.7億美元
預測年份 2032 31.2億美元
複合年成長率 (%) 6.92%

該計劃簡明扼要地概述了尿激酶科學、尖端製造技術和臨床作用，並培養能夠策略性地解讀詳細研究結果的領導者。

尿激酶仍然是一種至關重要的溶栓藥物，具有獨特的臨床特性，並在多種治療環境中持續效用。尿激酶最初來自人體，如今擴大透過重組生物技術生產，並已被證明對臨床醫生而言具有不可估量的價值，可作為術中輔助性治療和治療危及生命的血栓事件的全身療法。其動態特性，加上不斷發展的生產流程，正促使臨床專家和生物製藥生產商對尿激酶重新燃起戰略興趣。

這是一個重要的技術、臨床和監管轉折點，它正在重新定義尿激酶在醫療保健環境中的生產、配方選擇和治療應用。

尿激酶市場格局正受到相互關聯的技術、監管和臨床趨勢的重塑，這些趨勢共同加速了產品創新和策略定位的調整。重組表達平台的進步降低了變異性並提高了可擴展性，使新參與企業和現有生物製藥企業能夠重新評估製造地和成本結構。同時，製劑技術的改進，特別是冷凍乾燥和穩定輔料技術的改進，提高了儲存穩定性並簡化了低溫運輸要求，從而擴大了尿激酶的應用範圍。

2025 年關稅體系如何重組籌資策略、庫存計劃和商業契約，以增強供應彈性和成本可預測性。

2025年的關稅調整為全球生物製藥供應鏈帶來了新的成本因素，促使生產商和經銷商重新評估其採購和物流策略。對於依賴跨境採購原料、初級包裝或契約製造服務的公司而言，當務之急是重組與供應商的關係，並尋找能夠在保證品質的前提下降低額外接收成本的替代方案。這些貿易政策的變化對採購前置作業時間產生了連鎖反應，各公司紛紛調整訂單以減輕關稅區波動的影響。

我們透過提供產品類型、配方偏好、臨床用途、最終用戶和分銷管道的詳細細分觀點，來支援選擇合適的商業化產品。

產品類型細分揭示了兩條主要的研發路徑：一條是人源生技藥品，其特點是具有悠久的應用歷史和已確立的臨床親和性；另一條是重組尿激酶，其透過生物技術表達系統生產，可實現可控生產和規模化生產。在重組路徑中，大腸桿菌表現和哺乳動物細胞表現之間的差異會影響糖譜、免疫抗原性原性以及下游製程複雜性等特性，進而影響監管要求和生產成本結構。

影響監管方法、製造選擇和商業化策略的美洲、歐洲、中東和非洲以及亞太地區的區域趨勢比較。

在美洲，醫療保健系統高度專業化，成熟的醫院系統重視正式的採購合約和嚴格的支付方評估。該地區更傾向於選擇具有強力臨床證據且能明確納入醫院處方清單的產品，且物流能力通常足以支持複雜的低溫運輸運作。因此，優先考慮該地區的製造商通常會專注於臨床試驗項目和醫院合作策略，以確保其產品能夠被三級和四級醫療中心採用。

業務重點、夥伴關係策略和證據產生方法使尿激酶領域的主要企業脫穎而出，並定義了它們的競爭定位。

尿激酶產業的企業正著力於多項策略重點，以提升自身競爭力。首先，企業高度重視生產的可靠性和合規性。他們正投資建造符合GMP標準的生產設施、進行製程驗證並完善品質體系，以確保持續向醫療機構供應產品。其次，企業擴大利用與合約研發生產機構（CDMO）、臨床研究網路和分銷專家的策略夥伴關係，以加快市場准入速度並降低資本風險。

為製造商和經銷商提供戰術性和結構措施，以增強尿激酶產品的韌性，制定循證策略，實現配方差異化，並改善市場進入。

產業領導企業應優先考慮供應鏈韌性，對關鍵原料實施雙源採購策略，並評估關鍵製造流程的近岸外包方案。將這些措施與強化庫存管理和情境規劃結合，可以降低外部政策變化和物流中斷帶來的風險。同時，投資模組化製造技術和可擴展的表達平台將縮短產品上市時間，改善成本控制，並提高響應臨床需求的靈活性。

結合專家訪談、監管審查和流程圖繪製的綜合混合方法，可為利害關係人提供檢驗且可操作的見解。

本分析整合了來自一手和二手調查的數據，建構了可靠的證據基礎。一手調查包括對臨床醫生、醫院藥劑師、監管專家和供應鏈管理人員進行結構化訪談，以收集關於臨床效用、採購慣例和生產限制的第一手觀點。除這些訪談外，還與參與生物製藥生產和研發的專家舉行了圓桌討論和諮詢，以檢驗技術假設並闡明營運方面的權衡取捨。

策略整合突顯了生產品質、特定適應症證據和以客戶為中心的商業化在推動尿激酶永續應用方面緊密聯繫的作用。

尿激酶處於成熟臨床效用與現代生技藥品創新交匯點，其生產製程選擇、製劑策略和實證實踐共同決定商業性成果。投資於可靠合規的生產流程，並將臨床證據與特定外科手術和溶栓應用案例相結合的相關人員，將更有利於獲得醫療機構的認可。同時，根據門診和專科醫療機構的需求調整產品劑型和分銷模式，將有助於擴大臨床應用範圍。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 尿激酶市場：依產品類型分類

  • 人類尿激酶
  • 重組尿激酶
    • 大腸桿菌表達
    • 哺乳動物細胞表達

第9章 尿激酶市場：依形式分類

  • 液體溶液
  • 粉末

第10章 尿激酶市場：依應用領域分類

  • 心血管外科
    • 冠狀動脈繞道手術手術
    • 瓣膜置換術
  • 溶栓治療
    • 急性心肌梗塞
    • 肺動脈栓塞

第11章 尿激酶市場：依最終用戶分類

  • 門診手術中心
  • 診斷中心
  • 醫院
  • 專科診所

第12章 尿激酶市場：依分銷管道分類

  • 醫院藥房
  • 線上銷售
  • 零售藥房

第13章 尿激酶市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 尿激酶市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 尿激酶市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國尿激酶市場

第17章：中國尿激酶市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Cerbios-Pharma SA
  • Guangdong Techpool Bio-Pharmaceutical Co., Ltd.
  • Hanways Chempharm
  • Kraeber & Co GmbH
  • LIVZON
  • Medac GmbH
  • Microbix Biosystems Inc.
  • Parchem Fine & Specialty Chemicals
  • Taj Pharmaceuticals Ltd.
  • Wanhua Biochem
  • Zydus
Product Code: MRR-0355054AC506

The Urokinase Market was valued at USD 1.95 billion in 2025 and is projected to grow to USD 2.07 billion in 2026, with a CAGR of 6.92%, reaching USD 3.12 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.95 billion
Estimated Year [2026] USD 2.07 billion
Forecast Year [2032] USD 3.12 billion
CAGR (%) 6.92%

A concise orientation to urokinase science, contemporary manufacturing approaches, and clinical roles to prepare leaders for strategic interpretation of detailed insights

Urokinase remains a pivotal thrombolytic agent with a distinct clinical profile and enduring utility across diverse therapeutic contexts. Historically derived from human sources and increasingly produced through recombinant biotechnology, urokinase serves clinicians as both an intraoperative adjunct and a systemic therapy for life-threatening thrombotic events. Its pharmacodynamic characteristics, combined with evolving manufacturing pathways, make it a subject of renewed strategic interest among clinical leaders and biologics manufacturers alike.

Over recent years, technological advances in expression systems and formulation science have broadened the product landscape, prompting stakeholders to reassess supply chain configurations, regulatory strategies, and clinical positioning. Concurrently, shifts in healthcare delivery models and distribution channels have amplified the need for greater clarity around end-user demand dynamics and procurement preferences.

This introduction frames the subsequent analysis by outlining the biochemical rationale for urokinase use, clarifying the principal manufacturing modalities, and situating clinical applications within contemporary care pathways. By establishing this baseline, the report primes decision-makers to interpret downstream sections that explore structural shifts, tariff impacts, segmentation insights, regional dynamics, corporate behaviors, and practical recommendations.

Key technological, clinical, and regulatory inflection points that are redefining urokinase production, formulation choices, and therapeutic uptake across care settings

The urokinase landscape is being reshaped by interconnected technological, regulatory, and clinical trends that together accelerate product innovation and strategic repositioning. Advances in recombinant expression platforms have reduced variability and improved scalability, thereby enabling new entrants and incumbent biologics producers to revisit manufacturing footprints and cost structures. Parallel improvements in formulation-particularly lyophilization and stabilizing excipients-have expanded the practicable settings for administration by improving shelf stability and simplifying cold chain requirements.

On the clinical front, evolving guidelines and a growing evidence base for targeted thrombolysis in specific indications have influenced utilization patterns. This has encouraged clinicians to differentiate therapeutic choices based on pharmacokinetics, administration route, and bleeding risk profiles rather than relying solely on legacy preferences. Simultaneously, healthcare systems are emphasizing outpatient and ambulatory delivery models, pressuring manufacturers and distributors to adapt packaging, dosing formats, and service offerings to meet decentralized care needs.

Regulatory expectations are also shifting toward greater emphasis on comparability data for recombinant biologics, enhanced pharmacovigilance, and lifecycle evidence generation. These combined shifts create both opportunity and complexity for stakeholders seeking to optimize clinical adoption, supply reliability, and commercial viability. Consequently, organizations must coordinate clinical evidence strategies with manufacturing investments and market access planning to stay competitive.

How the 2025 tariff regime reshaped sourcing strategies, inventory planning, and commercial contracting to reinforce supply resilience and cost predictability

The 2025 tariff adjustments introduced new cost vectors across global biologics supply chains, prompting manufacturers and distributors to reassess sourcing and logistics strategies. For entities relying on cross-border procurement of raw materials, primary packaging, or contract manufacturing services, the immediate response centered on reconfiguring vendor relationships and identifying alternatives that preserved quality while mitigating incremental landed costs. These trade policy changes produced a ripple effect in procurement lead times as organizations shifted orders to mitigate exposure to variable tariff bands.

In response, several organizations prioritized onshoring or nearshoring of critical manufacturing steps to gain greater control over cost predictability and regulatory oversight. Investment decisions increasingly emphasized dual-sourcing strategies and enhanced inventory buffers for key intermediates to reduce vulnerability to tariff-driven disruptions. At the same time, distributors evaluated pricing models and contracting terms; longer-term supply agreements were renegotiated to include tariff mitigation clauses or to lock in volume discounts that offset heightened duties.

Clinicians and institutional buyers experienced transitional pricing pressure as organizations absorbed portions of cost increases to preserve market access. Looking ahead, procurement teams and manufacturer supply planners are integrating tariff sensitivity into scenario planning, emphasizing supplier diversity, and strengthening contractual protections to limit exposure to future policy volatility. These adaptations collectively illustrate how trade policy can catalyze structural realignments across the urokinase value chain.

In-depth segmentation perspectives on product types, formulation preferences, clinical applications, end users, and distribution channels to inform precise commercialization choices

Product type segmentation reveals two principal development pathways: biologics derived from human sources, characterized by historical use and established clinical familiarity, and recombinant urokinase produced through biotechnological expression systems that allow for controlled manufacturing and scalability. Within recombinant avenues, the divergence between Escherichia coli expression and mammalian cell expression informs attributes such as glycosylation profiles, immunogenicity considerations, and downstream processing complexity, which in turn influence regulatory dossiers and manufacturing cost structures.

Form-based differentiation between liquid solution and powder formulations has important implications for logistics and administration. Liquid solutions offer immediate readiness for use in acute settings but impose stricter cold chain and stability constraints, while powder formulations, typically lyophilized, can simplify storage and transport and enable reconstitution at point of care. These trade-offs affect hospital pharmacy inventory decisions and the feasibility of decentralized administration.

Application segmentation underscores distinct clinical pathways: cardiovascular surgery applications such as coronary artery bypass grafting and valve replacement require product attributes that support intraoperative use and compatibility with surgical protocols, whereas thrombolytic therapy applications, including acute myocardial infarction and pulmonary embolism, prioritize rapid systemic activity and predictable pharmacodynamics. Aligning clinical evidence and labeling to these differentiated use cases is essential for adoption.

End-user segmentation spans ambulatory surgical centers, diagnostic centers, hospitals, and specialty clinics, each with unique procurement cycles, storage capabilities, and clinical staffing profiles. Consequently, distribution channels including hospital pharmacy, online sales, and retail pharmacy must adapt commercial and service models to meet institutional purchasing terms, patient access needs, and regulatory requirements. Integrating these segmentation dimensions enables more precise product positioning, messaging, and operational planning.

Comparative regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence regulatory approaches, manufacturing choices, and commercialization tactics

In the Americas, healthcare systems exhibit a high degree of clinical specialization and established hospital systems that emphasize formal procurement contracts and rigorous payer assessments. This region tends to favor products with robust clinical evidence and clear pathways for hospital formulary inclusion, and logistics capabilities typically support advanced cold chain operations. As a result, manufacturers prioritizing this geography often emphasize clinical study programs and hospital engagement strategies to secure uptake within tertiary and quaternary centers.

The Europe, Middle East & Africa corridor presents heterogeneous regulatory frameworks and purchasing behaviors. Many countries in Europe maintain centralized health technology assessment processes that demand comparative clinical evidence and pharmacoeconomic rationale, while markets in the Middle East and Africa may prioritize supply chain reliability and price competitiveness. Manufacturers operating here often adopt differentiated market entry strategies that reconcile stringent regulatory expectations with the need for flexible distribution models adapted to diverse infrastructure capabilities.

In the Asia-Pacific region, rapid capacity expansion in biologics manufacturing and an increasing number of regional contract manufacturers have reshaped sourcing and cost considerations. Regulatory authorities across this region are advancing biologics guidelines in line with international standards, prompting manufacturers to invest in local clinical collaborations and regulatory alignment. Furthermore, the growing role of ambulatory and specialty care delivery in certain markets has driven demand for formulations and packaging that support decentralized administration. Together, these regional dynamics require companies to calibrate regulatory, manufacturing, and commercial plans to local health system priorities and operational realities.

Operational priorities, partnership strategies, and evidence generation approaches that distinguish leading organizations and inform competitive positioning in the urokinase domain

Companies active in the urokinase domain are converging on several strategic priorities that drive competitive differentiation. First, there is a pronounced focus on manufacturing reliability and compliance; firms are investing in GMP-certified capacity, process validation, and quality systems to ensure uninterrupted supply to institutional buyers. Second, strategic partnerships with contract development and manufacturing organizations, clinical research networks, and distribution specialists are increasingly used to accelerate market entry while controlling capital exposure.

Third, product development strategies vary between incremental formulation improvements-such as developing lyophilized presentations for enhanced stability-and deeper platform investments in recombinant expression systems that reduce batch variability and improve downstream yields. Fourth, commercial approaches emphasize two complementary pathways: direct engagement with hospital procurement teams for formulary inclusion and digital channels to support patient access and educational outreach for specialty clinics.

Finally, companies are prioritizing post-market evidence generation and pharmacovigilance to satisfy regulatory expectations and to build clinician confidence. These operational and strategic priorities collectively shape competition by privileging organizations that can integrate high-quality manufacturing, compelling clinical evidence, and adaptive commercial models into coherent offers for diverse healthcare settings.

Tactical and structural steps for manufacturers and distributors to enhance resilience, evidence strategies, formulation differentiation, and market access for urokinase offerings

Industry leaders should prioritize resilience in their supply chains by implementing dual-sourcing strategies for critical raw materials and by assessing nearshoring options for key manufacturing steps. Coupling these actions with expanded inventory governance and scenario planning will reduce exposure to external policy shifts and logistical disruptions. In parallel, investing in modular manufacturing technologies and scalable expression platforms can shorten time to product availability and improve cost control, enabling more flexible responses to clinical demand.

From a clinical and regulatory standpoint, organizations should align product development with indication-specific evidence generation. This means designing studies that address surgical use cases separately from systemic thrombolytic indications, and preparing regulatory dossiers that anticipate comparability queries for recombinant products. Stakeholders should also develop robust post-authorization safety and real-world evidence programs to support formulary discussions and payer negotiations.

Commercially, differentiating through formulation and service is critical: offering lyophilized formats, simplified reconstitution tools, specialized nurse training programs, and tailored logistics solutions will make products more attractive to both institutional buyers and decentralized care providers. Finally, pursue strategic partnerships across clinical networks, contract manufacturers, and distribution specialists to accelerate market access while maintaining quality and compliance. These integrated actions will position organizations to capture clinical opportunity while managing operational risk.

An integrated mixed methods approach combining expert interviews, regulatory review, and process mapping to produce validated and actionable insights for stakeholders

The analysis synthesizes primary and secondary research streams to construct a robust evidence base. Primary research comprised structured interviews with clinicians, hospital pharmacists, regulatory specialists, and supply chain managers to capture first-hand perspectives on clinical utility, procurement practices, and manufacturing constraints. These interviews were augmented by expert roundtables and consultations with professionals involved in biologics manufacturing and formulation development to validate technical assumptions and to contextualize operational trade-offs.

Secondary research drew on peer-reviewed scientific literature, regulatory guidance documents, clinical practice guidelines, and publicly available corporate disclosures to establish baseline factual context and to cross-verify themes emerging from primary interviews. Data triangulation techniques were applied to reconcile differences between sources and to identify consensus viewpoints. Quality assurance processes included methodological audits, source reliability checks, and iterative peer review by subject matter experts to ensure interpretive integrity.

Analytical approaches combined qualitative thematic analysis with quantitative process mapping-examining manufacturing workflows, cold chain dependencies, and distribution pathways-to identify vulnerabilities and opportunities. This mixed-methods approach ensured that conclusions and recommendations are grounded in both empirical observation and technical feasibility.

A strategic synthesis highlighting the intertwined roles of manufacturing quality, indication-specific evidence, and customer-centric commercialization in driving durable urokinase adoption

Urokinase sits at the intersection of established clinical utility and contemporary biologics innovation, creating a landscape where manufacturing choices, formulation strategies, and evidence programs jointly determine commercial outcomes. Stakeholders that invest in reliable, compliant manufacturing and that align clinical evidence to specific surgical and thrombolytic use cases will be better positioned to achieve institutional acceptance. At the same time, adapting product formats and distribution models to the needs of ambulatory and specialty care settings provides a pathway to broader clinical reach.

Trade policy shifts and regional regulatory heterogeneity underscore the importance of supply chain diversification and localized regulatory planning. Organizations that proactively integrate tariff sensitivity into sourcing decisions and that cultivate strategic partnerships for manufacturing and distribution will reduce operational risk and sustain access. Ultimately, the combination of robust quality systems, targeted clinical evidence, and customer-centric commercial models will determine which organizations successfully translate scientific potential into consistent patient access and institutional adoption.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Urokinase Market, by Product Type

  • 8.1. Human Urokinase
  • 8.2. Recombinant Urokinase
    • 8.2.1. Escherichia Coli Expression
    • 8.2.2. Mammalian Cell Expression

9. Urokinase Market, by Form

  • 9.1. Liquid Solution
  • 9.2. Powder

10. Urokinase Market, by Application

  • 10.1. Cardiovascular Surgery
    • 10.1.1. Coronary Artery Bypass Grafting
    • 10.1.2. Valve Replacement
  • 10.2. Thrombolytic Therapy
    • 10.2.1. Acute Myocardial Infarction
    • 10.2.2. Pulmonary Embolism

11. Urokinase Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Diagnostic Centers
  • 11.3. Hospitals
  • 11.4. Specialty Clinics

12. Urokinase Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Sales
  • 12.3. Retail Pharmacy

13. Urokinase Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Urokinase Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Urokinase Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Urokinase Market

17. China Urokinase Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Cerbios-Pharma SA
  • 18.6. Guangdong Techpool Bio-Pharmaceutical Co., Ltd.
  • 18.7. Hanways Chempharm
  • 18.8. Kraeber & Co GmbH
  • 18.9. LIVZON
  • 18.10. Medac GmbH
  • 18.11. Microbix Biosystems Inc.
  • 18.12. Parchem Fine & Specialty Chemicals
  • 18.13. Taj Pharmaceuticals Ltd.
  • 18.14. Wanhua Biochem
  • 18.15. Zydus

LIST OF FIGURES

  • FIGURE 1. GLOBAL UROKINASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL UROKINASE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL UROKINASE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL UROKINASE MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL UROKINASE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL UROKINASE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL UROKINASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL UROKINASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL UROKINASE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES UROKINASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA UROKINASE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL UROKINASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL UROKINASE MARKET SIZE, BY HUMAN UROKINASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL UROKINASE MARKET SIZE, BY HUMAN UROKINASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL UROKINASE MARKET SIZE, BY HUMAN UROKINASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL UROKINASE MARKET SIZE, BY ESCHERICHIA COLI EXPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL UROKINASE MARKET SIZE, BY ESCHERICHIA COLI EXPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL UROKINASE MARKET SIZE, BY ESCHERICHIA COLI EXPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL UROKINASE MARKET SIZE, BY MAMMALIAN CELL EXPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL UROKINASE MARKET SIZE, BY MAMMALIAN CELL EXPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL UROKINASE MARKET SIZE, BY MAMMALIAN CELL EXPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL UROKINASE MARKET SIZE, BY LIQUID SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL UROKINASE MARKET SIZE, BY LIQUID SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL UROKINASE MARKET SIZE, BY LIQUID SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL UROKINASE MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL UROKINASE MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL UROKINASE MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL UROKINASE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL UROKINASE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL UROKINASE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL UROKINASE MARKET SIZE, BY VALVE REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL UROKINASE MARKET SIZE, BY VALVE REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL UROKINASE MARKET SIZE, BY VALVE REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL UROKINASE MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL UROKINASE MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL UROKINASE MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL UROKINASE MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL UROKINASE MARKET SIZE, BY PULMONARY EMBOLISM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL UROKINASE MARKET SIZE, BY PULMONARY EMBOLISM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL UROKINASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL UROKINASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL UROKINASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL UROKINASE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL UROKINASE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL UROKINASE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL UROKINASE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL UROKINASE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL UROKINASE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL UROKINASE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL UROKINASE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL UROKINASE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL UROKINASE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL UROKINASE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL UROKINASE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL UROKINASE MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL UROKINASE MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL UROKINASE MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL UROKINASE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL UROKINASE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL UROKINASE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL UROKINASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS UROKINASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA UROKINASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA UROKINASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE UROKINASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST UROKINASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA UROKINASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC UROKINASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL UROKINASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN UROKINASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. GCC UROKINASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GCC UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. GCC UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 154. GCC UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. GCC UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 156. GCC UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GCC UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION UROKINASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS UROKINASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. G7 UROKINASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. G7 UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. G7 UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
  • TABLE 180. G7 UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 181. G7 UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. G7 UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 183. G7 UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. G7 UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. NATO UROKINASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. NATO UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. NATO UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
  • TABLE 189. NATO UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 190. NATO UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. NATO UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 192. NATO UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. NATO UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL UROKINASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES UROKINASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA UROKINASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA UROKINASE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA UROKINASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)